Natriumjodid (I-123) Curiumpharma (Sodium Iodide (123 I))

Sodium Iodide (I-123), the active ingredient in Natriumjodid (I-123) Curiumpharma, is a radiopharmaceutical presented as a solution for intravenous use. It is used for diagnostic imaging of thyroid function in patients requiring nuclear medicine evaluation.

GNH USA supplies Natriumjodid (I-123) Curiumpharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Natriumjodid (I-123) is employed in nuclear medicine to assess thyroid tissue uptake and function. - Thyroid imaging: provides high‑resolution images of thyroid anatomy and activity. - Thyroid scintigraphy: evaluates functional status of the gland in hyper‑ or hypothyroidism. - Thyroid nodule assessment: helps differentiate benign from malignant nodules based on iodine uptake patterns. - Post‑therapy monitoring: tracks thyroid tissue response after radioactive iodine treatment.

Adverse reactions are generally mild and related to the intravenous administration of a radioactive tracer.

Common Side Effects: - Nausea: transient feeling of queasiness after injection. - Mild headache: short‑lasting discomfort. - Warmth or flushing at the injection site. - Metallic taste in the mouth. - Transient hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate medical attention. - Radiation‑induced thyroiditis: inflammation of the thyroid gland. - Severe hypotension or cardiovascular collapse. - Radiation exposure to staff: requires strict safety protocols. - Bone marrow suppression (very rare): may affect blood cell production.

Prior to administration, several safety considerations should be observed. - Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: discontinue nursing for an appropriate period after dosing. - Thyroid disease: assess baseline thyroid function to interpret results accurately. - Radiation safety: ensure proper shielding and limit exposure to personnel. - Renal function: monitor in patients with impaired clearance as iodine is renally excreted. - Store at 2-8°C: keep refrigerated in lead‑lined container, protect from light, do not freeze.

Sodium Iodide (I-123) may interact with medications that influence iodine uptake or thyroid physiology.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): markedly reduce tracer uptake. - Lithium therapy: decreases iodine transport into the thyroid. - Amiodarone: high iodine load interferes with imaging accuracy. - High‑dose iodinated contrast agents: compete for the sodium‑iodide symporter.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may alter baseline uptake values. - Diuretics: affect renal clearance of iodine. - ACE inhibitors: can influence blood pressure response during injection. - Calcium supplements: may modestly reduce tracer accumulation. - Beta‑blockers: may mask symptoms of adverse cardiovascular reactions.